Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk

Dow Jones2025-12-27

11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com)

(END) Dow Jones Newswires

December 26, 2025 11:47 ET (16:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2594297111?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-27 00:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594297111","market":"nz","top_or_hot":-1,"title":"Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiohaven's Epilepsy Opportunity Seen Outshining Depression Trial -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-27 00:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2025 11:47 ET (16:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1093756325.SGD","symbol_name":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2594297111","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594297111","pubTimestamp":1766767620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"Biohaven的癫痫机会超过了抑郁症试验——市场讨论","themeId":"d018407bd33f27ba9ab8988ad29e6a0c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BHVN":0.9},"content_text":"11:47 ET - Biohaven still has strong potential despite a Phase 2 study of BHV-7000 not meeting its primary endpoint to treat depression, Raymond James analysts say. The analysts continue to rate the stock as a strong buy because they are focused on Biohaven's plans to develop BHV-7000 to treat epilepsy. BHV-7000 has a lot of promise as an epilepsy treatment, including a potentially best-in-class safety profile compared with competitor azetukalner, the analysts say. Biohaven plans to share data in January and have its first pivotal readout for epilepsy in the first half of 2026, which the analysts think will boost its near-term value. (katherine.hamilton@wsj.com) \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2025 11:47 ET (16:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594297111","isCrawlerRequest":true}